1. Home
  2. CRGX vs BAND Comparison

CRGX vs BAND Comparison

Compare CRGX & BAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • BAND
  • Stock Information
  • Founded
  • CRGX 2021
  • BAND 2000
  • Country
  • CRGX United States
  • BAND United States
  • Employees
  • CRGX N/A
  • BAND N/A
  • Industry
  • CRGX
  • BAND Computer Software: Prepackaged Software
  • Sector
  • CRGX
  • BAND Technology
  • Exchange
  • CRGX Nasdaq
  • BAND Nasdaq
  • Market Cap
  • CRGX 190.0M
  • BAND 358.3M
  • IPO Year
  • CRGX 2023
  • BAND 2017
  • Fundamental
  • Price
  • CRGX $4.46
  • BAND $16.05
  • Analyst Decision
  • CRGX Hold
  • BAND Buy
  • Analyst Count
  • CRGX 7
  • BAND 6
  • Target Price
  • CRGX $4.67
  • BAND $20.80
  • AVG Volume (30 Days)
  • CRGX 502.9K
  • BAND 271.8K
  • Earning Date
  • CRGX 08-11-2025
  • BAND 07-31-2025
  • Dividend Yield
  • CRGX N/A
  • BAND N/A
  • EPS Growth
  • CRGX N/A
  • BAND N/A
  • EPS
  • CRGX N/A
  • BAND N/A
  • Revenue
  • CRGX N/A
  • BAND $751,695,000.00
  • Revenue This Year
  • CRGX $57.81
  • BAND $2.41
  • Revenue Next Year
  • CRGX N/A
  • BAND $13.51
  • P/E Ratio
  • CRGX N/A
  • BAND N/A
  • Revenue Growth
  • CRGX N/A
  • BAND 18.51
  • 52 Week Low
  • CRGX $3.00
  • BAND $11.33
  • 52 Week High
  • CRGX $25.45
  • BAND $23.90
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 57.89
  • BAND 70.10
  • Support Level
  • CRGX $4.09
  • BAND $13.69
  • Resistance Level
  • CRGX $4.51
  • BAND $16.35
  • Average True Range (ATR)
  • CRGX 0.18
  • BAND 0.47
  • MACD
  • CRGX 0.00
  • BAND 0.19
  • Stochastic Oscillator
  • CRGX 77.18
  • BAND 97.79

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

About BAND Bandwidth Inc.

Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of our revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.

Share on Social Networks: